SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-23-267696
Filing Date
2023-11-01
Accepted
2023-11-01 07:08:00
Documents
14
Period of Report
2023-11-01
Items
Item 7.01: Regulation FD Disclosure
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d527979d8k.htm   iXBRL 8-K 44802
2 EX-99.1 d527979dex991.htm EX-99.1 27795
6 GRAPHIC g527979g1101113455835.jpg GRAPHIC 4962
  Complete submission text file 0001193125-23-267696.txt   214980

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA rvmd-20231101.xsd EX-101.SCH 2886
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE rvmd-20231101_lab.xml EX-101.LAB 17235
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE rvmd-20231101_pre.xml EX-101.PRE 10836
8 EXTRACTED XBRL INSTANCE DOCUMENT d527979d8k_htm.xml XML 3231
Mailing Address 700 SAGINAW DR REDWOOD CITY CA 94063
Business Address 700 SAGINAW DR REDWOOD CITY CA 94063 415-766-3638
Revolution Medicines, Inc. (Filer) CIK: 0001628171 (see all company filings)

IRS No.: 472029180 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39219 | Film No.: 231366537
SIC: 2836 Biological Products, (No Diagnostic Substances)